Hopstem Announces Phase I Clinical Data for iPSC-Derived Cell Therapy hNPC01 Injection

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

Dr. Fan Jing, founder and CEO of Hopstem Biotechnology, was invited to give a special report. The excellent efficacy data of hNPC01 in the Phase I clinical study conducted in China has attracted high attention from researchers and industry peers, marking that the high-quality clinical research of pluripotent stem cells in China is also at the forefront internationally.

"The scientific research and clinical achievements showcased at this year's symposium demonstrate that multiple pluripotent stem cell-derived therapies are entering the next critical stage of development," said Dr. Fan Jing. "We are honored to share the clinical data of hNPC01 on this global platform—a leading product in terms of progress and market scarcity, these forebrain neural precursor cells have already shown significant potential in treating long-term motor dysfunction after stroke in Phase I clinical trials. Hopstem Biotechnology will continue to advance the global clinical development of hNPC01, bringing safe, effective, accessible, and groundbreaking regenerative medicine therapies to patients with unmet clinical needs such as stroke and traumatic brain injury."”